Clinical trials: Extensive Disease Small Cell Lung Cancer
Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
This this study is for individuals who have treatment-naïve extensive-stage small cell lung cancer (small cell lung cancer that wont respond to treatment).
- Conditions
- Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer, Lung Cancer
- Trial name
- NCT05068232
- Testing
- Ablative Radiation, Durvalumab, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of Chicago
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Second-line Immunotherapy for ES-SCLC
At present, the first-line standard treatment for patients with extensive-stage small cell lung cancer (ES-SCLC) is immunotherapy combined with chemotherapy.
- Trial name
- NCT06853678
- Testing
- Adebrelimab, Selinexor, Nab-paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Small Cell Lung Cancer, Lung Cancer
Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).
Standard of care for Extensive-Stage Disease (ED) Small Cell Lung Cancer (SCLC) as first-line treatment is 4 to 6 cycles of platinum based chemotherapy (carboplatin or cisplatin) in combination with etoposide.
- Trial name
- NCT04472949
- Testing
- Durvalumab, carboplatin, etoposide
- Where
- 14 sites in Switzerland
- Volunteers
- 46 people
- Sponsor
- Swiss Cancer Institute
Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer
This phase II trial is studying how well sorafenib works in treating patients with extensive stage small cell lung cancer. Sorafenib may stop the growth of small cell lung cancer by blocking blood flow to the tumor and by…
- Trial name
- NCT00182689
- Testing
- sorafenib tosylate
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- National Cancer Institute (NCI)
ES-SCLC
Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
This study will evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Injection in combination with Chemotherapy and Sequential Thoracic Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer.
- Trial name
- NCT07349225
- Testing
- Iparomlimab and Tuvonralimab Injection, Etoposide, Cisplatin
- Volunteers
- 46 people
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
Extensive Stage Small Cell Lung Cancer
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC
This is an open-label, single-arm, prospective phase 2 study, evaluating the efficacy and safety of tislelizumab combined with Anlotinib as maintenance therapy following tislelizumab and chemotherapy for treatment naïve extensive…
- Trial name
- NCT05896059
- Testing
- Tislelizumab, Anlotinib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Zhejiang Cancer Hospital
SCLC
Adebrelimab + Apatinib in SCLC Maintenance Therapy
This prospective clinical study aims to evaluate and observe the efficacy and safety of Atezolizumab combined with Apatinib in maintenance therapy for extensive-stage small cell lung cancer using a single-arm trial design.
- Trial name
- NCT06475209
- Testing
- Adebrelimab combined with Apatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tang-Du Hospital
Small Cell Lung Carcinoma
Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
Maintenance durvalumab (MEDI4736) and olaparib (AZD2281) after standard 1st line treatment (carboplatin/ cisplatin, etoposide, durvalumab) in HRD positive extensive disease (ED) small-cell lung cancer (SCLC)
- Trial name
- GUIDANCE (NCT06419179)
- Testing
- Durvalumab, Olaparib
- Where
- Germany
- Volunteers
- 29 people
- Sponsor
- University of Cologne
Extensive Stage Small Cell Lung Carcinoma
MK-3475 as Maintenance Therapy in Extensive Stage SCLC
This phase II trial studies how well pembrolizumab works in treating patients with extensive stage small cell lung cancer after completion of combination chemotherapy.
- Trial name
- NCT02359019
- Testing
- Pembrolizumab, Laboratory Biomarker Analysis
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
SCLC, Extensive Stage
A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer
This is a single-center, single-arm, exploratory clinical study conducted at Shanghai Pulmonary Hospital, Tongji University. It aims to evaluate the efficacy and safety of first-line treatment with benmelstobart plus anlotinib…
- Trial name
- Aurora 005 (NCT07538271)
- Testing
- benmelstobart, Anlotinib, Carboplatin or cisplatin
- Volunteers
- 33 people
- Sponsor
- Yayi He
Small Cell Lung Cancer
Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer
The primary objective of the study is to provide expanded access to and characterize the safety profile of tarlatamab in participants with advanced small cell lung cancer (SCLC) after two or more prior lines of treatment…
- Trial name
- NCT06064500
- Testing
- Tarlatamab
- Where
- 23 sites in United States, Brazil and 2 more
- Sponsor
- Amgen
Small Cell Lung Cancer
A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
This is a Phase II, single-arm, single-center study evaluating Chidamide combined with a PD-L1 inhibitor, carboplatin, and etoposide as first-line therapy in extensive-stage small-cell lung cancer (ES-SCLC) patients.
- Trial name
- NCT07373964
- Testing
- Chidamide Tablets； PD-L1 Inhibitor (as per chosen drug's prescribing information)；Carboplatin； Etoposide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- China Medical University, China
Small Cell Lung Cancer
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.
- Trial name
- (DeLLphi-310) (NCT06898957)
- Testing
- YL201, Tarlatamab, Durvalumab
- Where
- 36 sites in United States, Canada and 8 more
- Volunteers
- 29 people
- Sponsor
- Amgen
Small Cell Lung Cancer
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
The purpose of the study is to test the effect of rovalpituzumab tesirine in the frontline treatment of small cell lung cancer (SCLC).
- Trial name
- NCT02819999
- Testing
- Rovalpituzumab Tesirine, Cisplatin, Etoposide
- Where
- 11 sites in United States
- Volunteers
- 28 people
- Sponsor
- AbbVie
Small-cell Lung Cancer
A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer
This study is conducted in patients with advanced metastatic small cell lung cancer (SCLC). This study includes a single arm: the patients will receive HLX07 combination therapy with HLX10 and chemotherapy (carboplatin+etoposide)…
- Trial name
- NCT05354700
- Testing
- HLX07, HLX10, carboplatin and etoposide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Henlius Biotech
Breast Cancer, Lung Cancer
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
RATIONALE: Gathering information about how often osteonecrosis of the jaw occurs in patients receiving zoledronic acid for bone metastases may help doctors learn more about the disease and provide the best follow-up care.
- Conditions
- Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma
- Trial name
- NCT00874211
- Testing
- assessment of therapy complications
- Where
- 453 sites in United States, Mexico and 1 more
- Volunteers
- 3,571 people
- Sponsor
- SWOG Cancer Research Network
Extensive Stage Small Cell Lung Cancer
A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer
The purpose of this study is to assess efficacy and safety of patients who receive Adebrelimab combined with chemotherapy±chest radiotherapy as first-line treatment of extensive stage small cell lung cancer in the real world.
- Trial name
- NCT06323265
- Testing
- Adebrelimab + chemotherapy, ±chest radiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Hebei Medical University Fourth Hospital
Lung Cancer, Extensive-stage Small-cell Lung Cancer
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
The purpose of this study was to evaluate the efficacy of low-dose radiotherapy (LDRT) combined with durvalumab, etoposide, and cisplatin/carboplatin in the first-line treatment of extensive-stage small cell lung cancer.
- Conditions
- Lung Cancer, Extensive-stage Small-cell Lung Cancer, Durvalumab
- Trial name
- NCT05092412
- Testing
- Low-dose radiotherapy, Durvalumab, Etoposide, and cisplatin/carboplatin
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- You Lu
Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer
Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
This phase I/II trial studies the side effects, safety, and effectiveness of low dose radiation to the entire body (total body irradiation [TBI]) and higher dose radiation to known areas of cancer (hypofractionated radiation…
- Trial name
- TESSERACT (NCT06110572)
- Testing
- Carboplatin, Atezolizumab, Etoposide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Small Cell Lung Cancer
Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC
This study involves being treated initially with a combination of drugs called irinotecan and cisplatin (induction therapy), followed by treatment with a drug called Gleevec (maintenance therapy).
- Trial name
- NCT00156286
- Testing
- Gleevec
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Michigan Rogel Cancer Center